Longitudinal feasibility of the Montreal Cognitive Assessment (MoCA) in non-demented ALS patients.
Journal
European neurology
ISSN: 1421-9913
Titre abrégé: Eur Neurol
Pays: Switzerland
ID NLM: 0150760
Informations de publication
Date de publication:
20 Apr 2024
20 Apr 2024
Historique:
received:
12
10
2023
accepted:
16
03
2024
medline:
22
4
2024
pubmed:
22
4
2024
entrez:
21
4
2024
Statut:
aheadofprint
Résumé
The present study aimed at testing the longitudinal feasibility of the Montreal Cognitive Assessment (MoCA) in an Italian cohort of non-demented amyotrophic lateral sclerosis (ALS) patients. N=39 non-demented ALS patients were followed-up at a 5-to-10-month interval (M=6.8; SD=1.4) with the MoCA and the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Practice effects, test-retest reliability and predictive validity (against follow-up ECAS scores) were assessed. Reliable change indices (RCIs) were derived via a regression-based approach by accounting for retest interval and baseline confounders (i.e., demographics, disease duration and severity and progression rate). At retest, 100% and 69.2% of patients completed the ECAS and the MoCA, respectively. Patients who could not complete the MoCA showed a slightly more severe and fast-progressing disease. The MoCA was not subject to practice effects (t(32)=-.80; p=.429) and was reliable at retest (ICC=.82). Moreover, baseline MoCA scores predicted the ECAS at retest. RCIs were successfully derived - with baseline MoCA scores being the only significant predictor of retest performances (ps<.001). As long as motor disabilities do not undermine its applicability, the MoCA appears to be longitudinally feasible at a 5-to-10-month interval in non-demented ALS patients. However, ALS-specific screeners - such as the ECAS - should be preferred whenever possible.
Identifiants
pubmed: 38643758
pii: 000538828
doi: 10.1159/000538828
doi:
Types de publication
News
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
S. Karger AG, Basel.